SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients

Summary

For those chronic hepatitis C patients, who are interferon-ineligible or intolerant, there is a burning need for the development of pan-oral interferon-free regimen. The investigators examine the efficacy and safety of sofosbuvir, a NS5B nucleotide polymerase inhibitor and daclatasvir, an NS5A replication complex inhibitor in Chinese treatment-experienced cirrhosis patients with chronic G1b infection.

Timeline

Start

2015-01

Primary completion

2017-12-31

Completion

2018-03-15

Drugs

Indications